Robert J. Schneider, PhD, Albert Sabin Professor of Molecular Pathogenesis, Professor of Microbiology, Professor of Radiation Oncology, NYU School of Medicine.
Dr. Schneider performs basic, translational and clinical research on the molecular basis of metastatic breast cancers, the intersection with the immune response, adult tissue regeneration and the development of new therapeutics in these areas. From 2013 until 2020 Dr. Schneider was also the inaugural Associate Dean at NYU Langone Health/NYU School of Medicine for the office of NYU Technology Ventures and Partnerships, the biomedical technology and drug development arm of NYU. Dr. Schneider is also a co-founding scientist of six biotechnology/small pharmaceutical companies, including ImClone Systems (New York), PTC Therapeutics. (New Jersey) Canji (San Diego), Gencell (Paris), Charterhouse Pharmaceuticals (London) and ENB Therapeutics (New York). Dr. Schneider received his Ph.D. in biophysical/biomedical sciences from the Mount Sinai School of Medicine and was a postdoctoral research fellow in the Department of Molecular Biology at Princeton University.
Scientific Shorts